Efficacy and safety of clarithromycin as treatment for Mediterranean spotted fever in children: a randomized controlled trial.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 11438914.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Fifty-one children with Mediterranean spotted fever (MSF) were randomized to receive either clarithromycin, 15 mg/kg/day orally in 2 divided doses, or chloramphenicol, 50 mg/kg/day orally in 4 divided doses, for 7 days. Mean time to defervescence was 36.7 h in the clarithromycin group and 47.1 h in the chloramphenicol group (P=.047). Clarithromycin could be an acceptable therapeutic alternative to chloramphenicol and to tetracyclines for children aged <8 years with MSF.
Medical subject headings
- Anti-Bacterial Agents
- Boutonneuse Fever
- Clarithromycin